The 30-second summary
- No randomised trial we could find has tested microdoses for any of these reasons. Everything below comes from licensed doses, or from weaker evidence such as chart reviews and case series.
- At licensed doses, some effects are real: lower markers of inflammation, less knee osteoarthritis pain, less food craving. Mood data are mixed: reassuring in trials, less so in one large record study.
- For autoimmune conditions, ADHD and anxiety, the evidence is thin. Do not replace treatment your specialist prescribes with a GLP-1, at any dose.
Why people microdose for more than weight
Online communities about microdosing talk about more than the scale. People describe calmer minds, less joint pain, fewer flares of inflammatory conditions and a quieter relationship with food and alcohol. Those experiences are real to the people having them. The question for anyone deciding what to do is which of them have been tested, at what dose, and how well.
First, the baseline. We could find no randomised trial of microdosed GLP-1 medicines on PubMed, for weight or for anything else. What has been published is commentary, including a 2026 report for nurse practitioners describing dosing errors and safety risks from manipulating pens, using compounded vials and buying unregulated peptides. (See GLP-1 microdosing and staying on a lower GLP-1 dose.)
Inflammation
The strongest data: SELECT. SELECT followed 17,604 adults with heart disease and overweight or obesity, but not diabetes, on semaglutide 2.4 mg or placebo. A prespecified analysis published in Circulation in 2026 looked at hsCRP, a blood marker of inflammation. Semaglutide lowered it by 37.8% at two years. The larger falls went with greater weight loss, but they began within 4 to 8 weeks, before major weight loss, and were also seen in people who did not lose weight. Lower hsCRP was linked to lower risk of heart attacks and strokes.
In type 2 diabetes. A 2026 meta-analysis of 41 randomised trials found GLP-1 medicines lowered CRP, while effects on other inflammatory markers such as IL-6 and TNF-alpha were less consistent. Two tirzepatide trials showed lower IL-6.
What this means for microdosing. These are licensed doses, in people with heart disease or diabetes. They show that GLP-1 medicines can lower inflammatory markers. They do not show that a fraction of the dose does the same, or that a lower number on a blood test improves any particular symptom you have. (See GLP-1 medicines and inflammation.)
Joint pain
Knee osteoarthritis: a proper trial. STEP 9, published in the New England Journal of Medicine in 2024, randomised 407 adults with obesity and painful knee osteoarthritis, 81.6% of them women, to semaglutide 2.4 mg or placebo for 68 weeks.
| Semaglutide 2.4 mg | Placebo | |
|---|---|---|
| Weight change | -13.7% | -3.2% |
| Knee pain score change (WOMAC, 0 to 100) | -41.7 points | -27.5 points |
| Physical function score change (SF-36) | +12.0 points | +6.5 points |
The trial's own background notes that weight loss eases knee osteoarthritis pain, so it cannot separate the effect of the medicine from the effect of the weight lost. Pain also fell a good deal on placebo. (See semaglutide and knee pain and joints on a GLP-1.)
Autoimmune and inflammatory conditions
The evidence here varies a great deal in quality.
- Psoriasis: one randomised trial. A 2026 open-label randomised trial in 274 adults with moderate to severe psoriasis and overweight or obesity added tirzepatide to the biologic ixekizumab. At 36 weeks, 27.1% reached both completely clear skin and 10% weight loss, against 5.8% on ixekizumab alone. Completely clear skin on its own was reached by 40.6% against 29.0%.
- Rheumatoid arthritis: a chart review. A 2025 retrospective study compared 173 people with rheumatoid arthritis who took semaglutide or tirzepatide with 42 who were prescribed one but did not take it, and found greater falls in disease activity and pain in those who took it. Nearly a third stopped the medicine during the year. Looking back at records cannot rule out other explanations.
- Mast cell activation syndrome: a case series. A 2025 series of 47 patients reported benefit in 89%, with no comparison group. The authors themselves say randomised trials are needed.
- Hashimoto's thyroiditis: case reports only. We found no trial.
None of these studies used microdoses. If you have an autoimmune condition, involve the specialist who treats it before adding a GLP-1, and do not stop your usual treatment. (See GLP-1 medicines and autoimmune conditions and the thyroid.)
The calmer mind
Food and cravings. Controlled trials show less food craving and better control of eating on semaglutide, and less craving and less reaction to food in their surroundings on tirzepatide. For many people, that alone changes how the day feels. (See food noise.)
Alcohol. A 2025 randomised trial in 48 adults with alcohol use disorder gave low starting doses of semaglutide, 0.25 mg rising to 0.5 mg, with 1 mg in the final week, for 9 weeks in all. It reduced how much people drank in a laboratory test, drinks per drinking day and alcohol craving, though not the number of drinking days. It was small and short, but it is one of the few trials of low doses for anything beyond weight. (See GLP-1 medicines and alcohol.)
Mood safety. A 2024 pooled analysis of the STEP 1, 2, 3 and 5 trials, in people without major psychiatric illness, found depression scores were very slightly better on semaglutide 2.4 mg than placebo, and suicidal thoughts or behaviour were reported by 1% or fewer, with no difference between groups. In April 2024, the European Medicines Agency's safety committee concluded that the available evidence does not support a causal link between GLP-1 medicines, including semaglutide, and suicidal or self-injurious thoughts.
But not everyone feels calmer. A 2026 study of health records from 13 South Korean hospitals compared 2,357 people who started semaglutide for weight loss with matched people who did not. Those on semaglutide were diagnosed with an anxiety disorder at about 2.4 times the rate, and a depressive disorder at about 3.4 times, with wide margins of uncertainty. Record studies cannot prove cause, but they are a reason to watch. Separately, a 2026 review of the records of 226 people on GLP-1 medicines found most people's existing depression or anxiety stayed stable, but new or worsening psychiatric symptoms appeared in a minority. (See GLP-1 medicines and anxiety and mood.)
ADHD. There is no trial of GLP-1 medicines for ADHD. The same 2026 chart review recorded new ADHD diagnoses in some people during treatment, which tells us nothing about benefit. Do not use a GLP-1 in place of ADHD treatment.
Putting it together
| Hope | Best evidence | At microdoses? |
|---|---|---|
| Lower inflammation | Large trials at licensed doses show lower CRP | Not tested |
| Less knee pain | Randomised trial at 2.4 mg, tangled with weight loss | Not tested |
| Autoimmune conditions | One open-label psoriasis trial; otherwise chart reviews, case series and case reports | Not tested |
| Less craving, food or alcohol | Trials at licensed or starting doses | Not tested |
| Calmer mood, less anxiety | Trials reassuring on depression; one large record study found more anxiety diagnoses; no trial for anxiety | Not tested |
| ADHD | None | Not tested |
What to do with this
If any of these is your reason for considering a GLP-1, take it to a prescriber, and to the specialist who manages the condition, rather than a forum. Ask what dose has actually been studied for it, what the alternatives are, and how you will both know whether it is working. And whatever the reason, eating enough protein on a smaller appetite still matters. The calculator works out your protein floor and calorie target.
Sources
- Plutzky J, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation 2026. PubMed
- Kanbay M, et al. Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab 2026. PubMed
- Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med 2024. PubMed
- Lebwohl M, et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol 2026. PubMed
- Kellner DA, et al. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. ACR Open Rheumatol 2025. PubMed
- Afrin LB, et al. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. Am J Med Sci 2025. PubMed
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025. PubMed
- Wadden TA, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med 2024. PubMed
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. ema.europa.eu
- Park J, et al. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study. Diabetes Obes Metab 2026. PubMed
- Sa B, et al. Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage. J Psychiatr Res 2026. PubMed
- Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021. PubMed
- Martin CK, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med 2025. PubMed
- Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract 2026. PubMed
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Do not start, stop or change any medicine, including treatment for an autoimmune condition, ADHD, anxiety or depression, without your prescriber. See our full medical disclaimer.